Diamino-Pyridine H4 Receptor Modulators for Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for potent histamine H4 receptor modulators with desirable pharmaceutical properties to effectively treat various diseases and disorders mediated by histamine H4 receptor activity, including inflammatory responses, allergic reactions, and autoimmune diseases.
Innovation Solution
Development of certain diamino-pyridine, pyrimidine, and pyridazine compounds that act as histamine H4 receptor modulators, inhibiting leukocyte recruitment and releasing inflammatory mediators, thereby providing anti-inflammatory and anti-pruritic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing H4 receptor modulators are used, then H4 receptor activity is modulated, but potent efficacy and desirable pharmaceutical properties are not simultaneously achieved
Solution Approach 1:
The patent modifies molecular parameters of H4 receptor modulators by introducing specific diamino-pyridine, pyrimidine, and pyridazine core structures with defined substituents (R1-R6 groups). These structural parameter changes enable simultaneous achievement of potent efficacy and desirable pharmaceutical properties including selective binding, appropriate pharmacokinetics, and reduced off-target effects.
2Reliability
If leukocyte recruitment is inhibited, then anti-inflammatory effect is improved, but mechanism specificity and selectivity are not optimized
Solution Approach 1:
The patent employs local quality by creating H4 receptor-specific molecular interactions through the diamino-pyridine, pyrimidine, and pyridazine core structures. These structures provide selective binding at the H4 receptor site with high mechanism specificity, enabling anti-inflammatory effect through localized action at the receptor level without non-specific effects.
Solution Approach 2:
The patent uses the H4 receptor itself as an intermediary target. The modulators bind specifically to the H4 receptor, which mediates the anti-inflammatory effect by inhibiting leukocyte recruitment. This intermediary approach ensures mechanism specificity as the effect is transmitted through the well-defined H4 receptor signaling pathway.
3Reliability
If inflammatory mediators are released, then anti-pruritic effect is improved, but control over mediator release timing and location is not achieved
Solution Approach 1:
The patent employs feedback through the H4 receptor signaling pathway. The modulators bind to H4 receptors on mast cells and other immune cells, providing feedback inhibition that controls the release of inflammatory mediators. This feedback mechanism ensures controlled mediator release timing and location, improving anti-pruritic effect while maintaining ease of operation through natural physiological regulation.
Data Source
AI summary
Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as H4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.